Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q1 2025 ▲▼ | Q2 2025 ▲▼ | Change ▲▼ | Q1 2025 ▲▼ | Q2 2025 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Rezolute, Inc.(RZLT) | 1,318,967 | 1,603,986 | +285,019 | $3.83M | $7.15M | 72.60% | +$3.33M |
| SPDR Gold SharesGOLD SHS(GLD) | 1,298 | 4,952 | +3,654 | $374.1K | $1.51M | 15.32% | +$1.14M |
| Berkshire Hathaway Inc DelCL B | 467 | 632 | +165 | $248.8K | $307.0K | 3.12% | +$58.2K |
| Enliven Therapeutics Inc | 0 | 13,097 | +13,097 | $0 | $262.7K | 2.67% | +$262.7K |
| Mind Medicine Mindmed Inc | 34,073 | 34,073 | 0 | $199.3K | $221.1K | 2.24% | +$21.8K |
| Compass Therapeutics, Inc.(CMPX) | 43,465 | 43,465 | 0 | $82.6K | $113.0K | 1.15% | +$30.4K |
| Bicara Therapeutics Inc | 10,941 | 10,941 | 0 | $142.6K | $101.6K | 1.03% | -$40.9K |
| Kyverna Therapeutics, Inc.(KYTX) | 22,981 | 22,981 | 0 | $44.4K | $70.6K | 0.72% | +$26.2K |
| Lexeo Therapeutics, Inc.(LXEO) | 17,851 | 17,332 | -519 | $61.9K | $69.7K | 0.71% | +$7.7K |
| Inhibikase Therapeutics, Inc.(IKT) | 16,393 | 16,393 | 0 | $35.9K | $32.0K | 0.32% | -$3.9K |
| Context Therapeutics Inc.(CNTX) | 18,403 | 18,403 | 0 | $11.3K | $12.1K | 0.12% | +$795 |
| Adicet Bio Inc | 17,488 | 0 | -17,488 | $13.2K | $0 | — | -$13.2K |
| Cardiff Oncology, Inc.(CRDF) | 13,287 | 0 | -13,287 | $41.7K | $0 | — | -$41.7K |